Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

SEER Cancer Statistics Review, 1975-2003

2006 • 11,387 citations

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2003 • 3,532 citations

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

2010 • 1,604 citations

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2010 • 1,520 citations

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

2009 • 1,306 citations

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

2006 • 1,296 citations

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

2006 • 1,199 citations

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate

2006 • 1,126 citations

Prognostic discrimination in "good-risk" chronic granulocytic leukemia

1984 • 989 citations

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

2009 • 849 citations

A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group

1998 • 823 citations

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation

1998 • 665 citations

Interferon Alfa-2a as Compared with Conventional Chemotherapy for the Treatment of Chronic Myeloid Leukemia

1994 • 592 citations

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

2008 • 566 citations

Chronic myeloid leukaemia

2007 • 490 citations

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology

1999 • 389 citations

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

2008 • 388 citations

Chronic Granulocytic Leukemia

1976 • 351 citations

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

2008 • 337 citations

Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

2006 • 262 citations

Congestive heart failure is a rare event in patients receiving imatinib therapy

2007 • 252 citations

Evaluating the Older Patient with Cancer: Understanding Frailty and the Geriatric Assessment

2010 • 251 citations

Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival

1985 • 214 citations

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

2009 • 209 citations

Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

2006 • 208 citations

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

2009 • 192 citations

Epidemiology of chronic myeloid leukaemia (CML)

2009 • 147 citations

A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response

2007 • 129 citations

Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry.

1996 • 117 citations

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase

2010 • 109 citations

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome‐positive chronic myelogenous leukemia

2003 • 92 citations

Molecular response to imatinib in late chronic-phase chronic myeloid leukemia

2003 • 86 citations

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

2009 • 80 citations

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

2009 • 71 citations

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

2007 • 64 citations

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome

2008 • 55 citations

“Real-life” results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

2010 • 55 citations

Comparison Between Patients With Philadelphia-Positive Chronic Phase Chronic Myeloid Leukemia Who Obtained a Complete Cytogenetic Response Within 1 Year of Imatinib Therapy and Those Who Achieved Such a Response After 12 Months of Treatment

2006 • 44 citations

Age Disparity in the Dissemination of Imatinib for Treating Chronic Myeloid Leukemia

2010 • 43 citations

Results of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older

1996 • 42 citations

Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.

2003 • 42 citations

Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α

2003 • 25 citations

Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment

2004 • 22 citations

Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response.

2008 • 19 citations

Old Age

1987 • 18 citations

Interferon-α for the treatment of elderly patients with chronic myeloid leukaemia

1998 • 17 citations

Molecular Response to First Line Imatinib Therapy Is Predictive for Long Term Event Free Survival in Patients with Chronic Phase Chronic Myelogenous Leukemia – An Interim Analysis of the Randomized German CML Study IV

2008 • 16 citations

Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate

2010 • 9 citations

Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients

2008 • 8 citations